43 related articles for article (PubMed ID: 15265903)
1. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
[TBL] [Abstract][Full Text] [Related]
2. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
3. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum.
Smyth MJ; Kelly JM; Baxter AG; Körner H; Sedgwick JD
J Exp Med; 1998 Nov; 188(9):1611-9. PubMed ID: 9802973
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cells require perforin to clear West Nile virus from infected neurons.
Shrestha B; Samuel MA; Diamond MS
J Virol; 2006 Jan; 80(1):119-29. PubMed ID: 16352536
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic mechanisms employed by mouse T cells to destroy pancreatic β-cells.
Varanasi V; Avanesyan L; Schumann DM; Chervonsky AV
Diabetes; 2012 Nov; 61(11):2862-70. PubMed ID: 22773667
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo.
Li Q; Li L; Shi W; Jiang X; Xu Y; Gong F; Zhou M; Edwards CK; Li Z
Cancer Immunol Immunother; 2006 Dec; 55(12):1470-9. PubMed ID: 16555058
[TBL] [Abstract][Full Text] [Related]
7. NFIL3 contributes to cytotoxic T lymphocyte-mediated killing.
Douanne T; Strege K; Del Castillo Velasco-Herrera M; Rochussen AM; Adams DJ; Griffiths GM
Open Biol; 2024 Feb; 14(2):230456. PubMed ID: 38412963
[TBL] [Abstract][Full Text] [Related]
8. Dynamic CD8
Vermare A; Guérin MV; Peranzoni E; Bercovici N
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884605
[TBL] [Abstract][Full Text] [Related]
9. Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.
Furusawa A; Reiser J; Sadashivaiah K; Simpson H; Banerjee A
J Immunother; 2018; 41(2):53-63. PubMed ID: 29271784
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.
Thoreau M; Penny HL; Tan K; Regnier F; Weiss JM; Lee B; Johannes L; Dransart E; Le Bon A; Abastado JP; Tartour E; Trautmann A; Bercovici N
Oncotarget; 2015 Sep; 6(29):27832-46. PubMed ID: 26337837
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M; Scurti GM; Salem ML; Paulos CM; Garrett-Mayer E; Mehrotra S; Cole DJ
Cancer Immunol Immunother; 2015 May; 64(5):539-49. PubMed ID: 25676709
[TBL] [Abstract][Full Text] [Related]
12. Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.
Miller MR; Mandell JB; Beatty KM; Harvey SA; Rizzo MJ; Previte DM; Thorne SH; McKenna KC
Cancer Immunol Res; 2014 Dec; 2(12):1175-85. PubMed ID: 25248763
[TBL] [Abstract][Full Text] [Related]
13. DICE: A novel tumor surveillance mechanism-a new therapy for cancer?
Peter ME
Cell Cycle; 2014; 13(9):1373-8. PubMed ID: 24690893
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.
de Titta A; Ballester M; Julier Z; Nembrini C; Jeanbart L; van der Vlies AJ; Swartz MA; Hubbell JA
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19902-7. PubMed ID: 24248387
[TBL] [Abstract][Full Text] [Related]
15. T-cell modulatory properties of CD5 and its role in antitumor immune responses.
Tabbekh M; Mokrani-Hammani M; Bismuth G; Mami-Chouaib F
Oncoimmunology; 2013 Jan; 2(1):e22841. PubMed ID: 23483035
[TBL] [Abstract][Full Text] [Related]
16. Influence of CD8+ T regulatory cells on intraocular tumor development.
McKenna KC; Previte DM
Front Immunol; 2012; 3():303. PubMed ID: 23060881
[TBL] [Abstract][Full Text] [Related]
17. CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination.
Vicetti Miguel RD; Cherpes TL; Watson LJ; McKenna KC
J Immunol; 2010 Dec; 185(11):6706-18. PubMed ID: 21041723
[TBL] [Abstract][Full Text] [Related]
18. A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells.
McKenna KC; Vicetti Miguel RD; Beatty KM; Bilonick RA
J Leukoc Biol; 2011 Feb; 89(2):291-300. PubMed ID: 20959413
[TBL] [Abstract][Full Text] [Related]
19. Influence of immune privilege on ocular tumor development.
McKenna KC; Chen PW
Ocul Immunol Inflamm; 2010 Apr; 18(2):80-90. PubMed ID: 20370332
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
